<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Phys Med Biol</journal-id><journal-id journal-id-type="iso-abbrev">Phys Med Biol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Physics in medicine and biology</journal-title></journal-title-group><issn pub-type="ppub">0031-9155</issn><issn pub-type="epub">1361-6560</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC3835526</article-id><article-id pub-id-type="pmcid-ver">PMC3835526.1</article-id><article-id pub-id-type="pmcaid">3835526</article-id><article-id pub-id-type="pmcaiid">3835526</article-id><article-id pub-id-type="manuscript-id">NIHMS508271</article-id><article-id pub-id-type="pmid">20826898</article-id><article-id pub-id-type="doi">10.1088/0031-9155/55/19/007</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS508271</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA508271</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The biological effectiveness of targeted radionuclide therapy based on a whole-body pharmacokinetic model</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Grudzinski</surname><given-names initials="JJ">Joseph J</given-names></name><xref ref-type="aff" rid="A1">1</xref><email>grudzinski@wisc.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tom&#233;</surname><given-names initials="W">Wolfgang</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weichert</surname><given-names initials="JP">Jamey P</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jeraj</surname><given-names initials="R">Robert</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave, Madison, WI 53705, USA</aff><aff id="A2"><label>2</label>Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave, Madison, WI 53705, USA</aff><aff id="A3"><label>3</label>Department of Radiology, University of Wisconsin School of Medicine and Public Health, 1111 Highland Ave, Madison, WI 53705, USA</aff><aff id="A4"><label>4</label>Jozef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia</aff><pub-date pub-type="epub"><day>08</day><month>9</month><year>2010</year></pub-date><pub-date pub-type="ppub"><day>7</day><month>10</month><year>2010</year></pub-date><volume>55</volume><issue>19</issue><issue-id pub-id-type="pmc-issue-id">229985</issue-id><elocation-id>10.1088/0031-9155/55/19/007</elocation-id><pub-history><event event-type="nihms-submitted"><date><day>31</day><month>10</month><year>2013</year></date></event><event event-type="pmc-release"><date><day>20</day><month>11</month><year>2013</year></date></event><event event-type="pmc-live"><date><day>21</day><month>11</month><year>2013</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-05 22:06:41.443"><day>05</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2010 Institute of Physics and Engineering in Medicine</copyright-statement><copyright-year>2010</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms508271.pdf"/><abstract><p id="P1">Biologically effective dose (BED) may be more of a relevant quantity than absorbed dose for establishing tumour response relationships. By taking into account the dose rate and tissue-specific parameters such as repair and radiosensitivity, it is possible to compare the relative biological effects of different targeted radionuclide therapy (TRT) agents. The aim of this work was to develop an analytical tumour BED calculation for TRT that could predict a relative biological effect based on normal body and tumour pharmacokinetics. This work represents a step in the direction of establishing relative pharmacokinetic criteria of when the BED formalism is more applicable than absorbed dose for TRT. A previously established pharmacokinetic (PK) model for TRT was used and adapted into the BED formalism. An analytical equation for the protraction factor, which incorporates dose rate and repair rate, was derived. Dose rates within the normal body and tumour were related to the slopes of their time&#8211;activity curves which were determined by the ratios of their respective PK parameters. The relationships between the tumour influx-to-efflux ratio (<italic toggle="yes">k</italic><sub>34</sub>:<italic toggle="yes">k</italic><sub>43</sub>), central compartment efflux-to-influx ratio (<italic toggle="yes">k</italic><sub>12</sub>:<italic toggle="yes">k</italic><sub>21</sub>), central elimination (<italic toggle="yes">k</italic><sub>el</sub>), and tumour repair rate (<italic toggle="yes">&#956;</italic>), and tumour BED were investigated. As the <italic toggle="yes">k</italic><sub>34</sub>:<italic toggle="yes">k</italic><sub>43</sub> ratio increases and the <italic toggle="yes">k</italic><sub>12</sub>:<italic toggle="yes">k</italic><sub>21</sub> ratio decreases, the difference between tumour BED and <italic toggle="yes">D</italic> increases. In contrast, as the <italic toggle="yes">k</italic><sub>34</sub>:<italic toggle="yes">k</italic><sub>43</sub> ratios decrease and the <italic toggle="yes">k</italic><sub>12</sub>:<italic toggle="yes">k</italic><sub>21</sub> ratios increase, the tumour BED approaches <italic toggle="yes">D</italic>. At large <italic toggle="yes">k</italic><sub>34</sub>:<italic toggle="yes">k</italic><sub>43</sub> ratios, the difference between tumour BED and <italic toggle="yes">D</italic> increases to a maximum as <italic toggle="yes">k</italic><sub>el</sub> increases. At small <italic toggle="yes">k</italic><sub>34</sub>:<italic toggle="yes">k</italic><sub>43</sub> ratios, the tumour BED approaches <italic toggle="yes">D</italic> at very small <italic toggle="yes">k</italic><sub>el</sub>. At small <italic toggle="yes">&#956;</italic> and small <italic toggle="yes">k</italic><sub>34</sub>:<italic toggle="yes">k</italic><sub>43</sub> ratios, the tumour BED approaches <italic toggle="yes">D</italic>. For large <italic toggle="yes">k</italic><sub>34</sub>:<italic toggle="yes">k</italic><sub>43</sub> ratios, large <italic toggle="yes">&#956;</italic> values cause tumour BED to approach <italic toggle="yes">D</italic>. This work represents a step in the direction of establishing relative PK criteria of when the BED formalism is more applicable than absorbed dose for TRT. It also provides a framework by which the biological effects of different TRT agents can be compared in order to predict efficacy.</p></abstract><funding-group><award-group><funding-source country="United States">National Cancer Institute : NCI</funding-source><award-id>T32 CA009206 || CA</award-id></award-group><award-group><funding-source country="United States">National Cancer Institute : NCI</funding-source><award-id>T32 CA009206 || CA</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>